Advances in diagnosis and treatment of non-tuberculous mycobacterial lung disease

Diagn Microbiol Infect Dis. 2024 Jun;109(2):116254. doi: 10.1016/j.diagmicrobio.2024.116254. Epub 2024 Mar 12.

Abstract

The prevalence of Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) is increasing worldwide. The advancement in molecular diagnostic technology has greatly promoted the rapid diagnosis of NTM-PD clinically, and the pathogenic strains can be identified to the species level through molecular typing, which provides a reliable basis for treatment. In addition to the well-known PCR and mNGS methods, there are numerous alternative methods to identify NTM to the species level. The treatment of NTM-PD remains a challenging problem. Although clinical guidelines outline several treatment options for common NTM species infections, in most cases, the therapeutic outcomes of these drugs for NTM-PD often fall short of expectations. At present, the focus of research is to find more effective and more tolerable NTM-PD therapeutic drugs and regimens. In this paper, the latest diagnostic techniques, therapeutic drugs and methods, and prevention of NTM-PD are reviewed.

Keywords: Diagnosis; Molecular diagnostic techniques; Non-tuberculous mycobacteria pulmonary disease; Treatment.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Lung Diseases / diagnosis
  • Lung Diseases / drug therapy
  • Lung Diseases / microbiology
  • Molecular Diagnostic Techniques / methods
  • Mycobacterium Infections, Nontuberculous* / diagnosis
  • Mycobacterium Infections, Nontuberculous* / drug therapy
  • Mycobacterium Infections, Nontuberculous* / microbiology
  • Nontuberculous Mycobacteria* / classification
  • Nontuberculous Mycobacteria* / drug effects
  • Nontuberculous Mycobacteria* / genetics
  • Nontuberculous Mycobacteria* / isolation & purification

Substances

  • Anti-Bacterial Agents